Values as of: 2025-03-03
COMMON STOCK | Biotechnology |
Last Closing
USD 70.26Change
-3.24 (-4.41)%Market Cap
USD 14.22BVolume
2.45MAnalyst Target
USD 106.20Verdict
Verdict
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Company Website : https://www.incyte.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+3.52 (+0.73%) |
USD 123.21B |
| REGN | Regeneron Pharmaceuticals Inc |
-13.87 (-1.99%) |
USD 76.39B |
| ARGX | argenx NV ADR |
-2.06 (-0.33%) |
USD 40.41B |
| ALNY | Alnylam Pharmaceuticals Inc |
-3.22 (-1.30%) |
USD 31.94B |
| ONC | BeiGene, Ltd. |
-26.27 (-9.67%) |
USD 25.62B |
| RPRX | Royalty Pharma Plc |
+0.22 (+0.65%) |
USD 18.65B |
| SMMT | Summit Therapeutics PLC |
-1.56 (-7.54%) |
USD 17.01B |
| UTHR | United Therapeutics Corporatio.. |
-10.02 (-3.13%) |
USD 14.37B |
| INSM | Insmed Inc |
-5.26 (-6.45%) |
USD 13.70B |
| BMRN | Biomarin Pharmaceutical Inc |
-0.14 (-0.20%) |
USD 13.58B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| XDNA:CA | iShares Genomics Immunolo.. | 4.27 % | 0.00 % |
-0.52 (0.12%) |
CAD 5.00M |
| CURE:AU | ETFS S&P Biotech ETF | 2.38 % | 0.00 % |
+1.25 (+0.12%) |
USD 0.04B |
| SAGP | The Advisorsa Inner Circl.. | 2.04 % | 0.00 % |
+0.04 (+0.12%) |
USD 0.04B |
| MRND | 1.89 % | 0.00 % |
N/A |
N/A | |
| BIS | ProShares UltraShort Nasd.. | 0.00 % | 0.95 % |
+0.67 (+0.12%) |
USD 3.30M |
| FBT | First Trust NYSE Arca Bio.. | 0.00 % | 0.57 % |
-4.01 (0.12%) |
N/A |
| GURU | Global X Guru Index ETF | 0.00 % | 0.75 % |
-1.31 (0.12%) |
N/A |
| LABU | Direxion Daily S&P Biotec.. | 0.00 % | 1.14 % |
-8.59 (0.12%) |
USD 0.77B |
| PBE | Invesco Dynamic Biotechno.. | 0.00 % | 0.57 % |
-1.22 (0.12%) |
N/A |
| JSMD | Janus Henderson Small/Mid.. | 0.00 % | 0.50 % |
-2.16 (0.12%) |
USD 0.45B |
| ZHU:CA | BMO Equal Weight US Healt.. | 0.00 % | 0.00 % |
+0.18 (+0.12%) |
CAD 0.01B |
| IDNA | iShares Genomics Immunolo.. | 0.00 % | 0.00 % |
-0.58 (0.12%) |
USD 0.12B |
| UBIO | 0.00 % | 0.95 % |
N/A |
N/A | |
| ZBIO | Zenas BioPharma, Inc. Com.. | 0.00 % | 0.95 % |
-0.37 (0.12%) |
N/A |
| ZUH:CA | BMO Equal Weight US Healt.. | 0.00 % | 0.39 % |
-0.41 (0.12%) |
CAD 0.22B |
| FBT:LSE | First Trust Global Funds .. | 0.00 % | 0.00 % |
-12.90 (0.12%) |
USD 8.65M |
| FBTU:LSE | First Trust Global Funds .. | 0.00 % | 0.00 % |
+0.04 (+0.12%) |
USD 8.62M |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 1.72% | 75% | C | 67% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1.72% | 75% | C | 67% | D+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 17.65% | 84% | B | 76% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 17.65% | 84% | B | 74% | C | ||
| Trailing 5 Years | |||||||
| Capital Gain | -12.35% | 73% | C | 43% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -12.35% | 73% | C | 38% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -8.54% | 37% | F | 23% | F | ||
| Dividend Return | -8.54% | 37% | F | 22% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 16.89% | 97% | N/A | 82% | B | ||
| Risk Adjusted Return | -50.57% | 21% | F | 13% | F | ||
| Market Capitalization | 14.22B | 99% | N/A | 94% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
